Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
October 26 2020 - 8:16AM
Business Wire
Promotion follows the Company’s achievement of
key manufacturing milestones to support upcoming clinical
trials
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
announced today the promotion of Eric Chapdelaine to Vice President
of Manufacturing. Mr. Chapdelaine’s promotion is a result of the
Company’s achievement of key manufacturing milestones to support
upcoming clinical trials of the Company’s lead drug candidate,
GPX-001 (quaratusugene ozeplasmid). Upcoming trials include a Phase
I/II trial combining GPX-001 with AstraZeneca’s Tagrisso®
(osimertinib) in non-small cell lung cancer (NSCLC) patients who
progressed on Tagrisso, which received U.S. Food and Drug
Administration (FDA) Fast Track Designation in January 2020.
“The appointment of Eric to our senior team is a hallmark of our
manufacturing achievements and highlights the progress we have made
in scaling up our manufacturing to commercial scale, which will
further supply our upcoming clinical trials,” said Michael Redman,
Genprex’s Executive Vice President and Chief Operating Officer.
In June of 2020, Genprex announced the expansion of its
commercial development program for the manufacture of TUSC2 (Tumor
Supressor Candidate 2) plasmid DNA, the active agent in GPX-001.
The program expansion provides for full commercial scale plasmid
DNA manufacturing with a key manufacturing partner. This
relationship is supporting the manufacture of the drug product,
GPX-001, to supply the Company’s upcoming clinical trials in which
GPX-001 is combined with Tagrisso and Keytruda® (marketed by
Merck), respectively.
Mr. Chapdelaine has more than 15 years of experience in the
pharmaceutical and biotech industries. He joined Genprex in 2019 as
Senior Director of Pharmaceutical Sciences and Manufacturing, where
he has been responsible for leading the Company’s Manufacturing
Operations and Supply Chain functions. Prior to joining Genprex,
Mr. Chapdelaine was Director of Quality Control and Analytical
Development at Cognate BioServices, responsible for management and
oversight of a large Quality Control and Analytical Development
staff and multiple laboratories in a Cell and Gene Therapy CDMO
facility. Prior to Cognate, he served as Quality Control Manager of
Specifications at Alnylam Pharmaceuticals, where he led as
Specification Committee Chairperson and authored CMC-related
sections of regulatory filings for the first ever approved RNAi
therapeutic for commercial use. Mr. Chapdelaine spent the prior six
years at Sanofi Genzyme.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches. The
Company’s lead product candidate, GPX-001 (quaratusugene
ozeplasmid), is being evaluated as a treatment for non-small cell
lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action
that has been shown to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells; re-establish
pathways for apoptosis, or programmed cell death, in cancer cells;
and modulate the immune response against cancer cells. GPX-001 has
also been shown to block mechanisms that create drug resistance. In
January 2020, the U.S. Food and Drug Administration granted Fast
Track Designation for GPX-001 for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone. For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of GPX-001, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining FDA approval of GPX-001 and our other potential product
candidates including whether we receive fast track or similar
regulatory designations; costs associated with developing our
product candidates and whether patents will ever be issued under
patent applications that are the subject of our license agreements.
These and other risks and uncertainties are described more fully
under the caption “Risk Factors” and elsewhere in our filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005129/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024